Navigation Links
Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid
Date:7/17/2009

all TSX requirements for continued listing, failing which the Share will be delisted from the TSX 30 days thereafter. The Corporation is, therefore, considering its options in this regard, which may include applying for a transfer of its listing to the TSX Venture Exchange or the NEX Board of the TSX Venture Exchange. Any decision in this regard will be made well in advance of the TSX deadline.

About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

Bradmer Pharmaceuticals' lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. Bradmer initiated enrollment of primary GBM patients in a Phase III multi-center clinical trial of Neuradiab. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regula
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Bradmer announces 2009 first quarter operational and financial results
2. Bradmer announces 2008 fourth quarter and fiscal year operational and financial results
3. Bradmer implements cash conservation plan
4. Bradmer provides clinical trial update and announces evaluation of strategic alternatives
5. Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
6. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
7. Bradmer announces 2008 third quarter operational and financial results
8. Bradmer to present at Rodman & Renshaw Healthcare Conference
9. Bradmer receives FDA approval to proceed with Phase III clinical trial
10. Bradmer announces 2008 first quarter operational and financial results
11. Bradmer announces new additions to management team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. ... fast approaching, a new study reveals that states that routinely ... drunk drivers on their roads. The finding suggests that ... able to deter inebriated revelers from getting behind the wheel ... being passed regarding drinking and driving," said study lead author ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Veretekk.com, Inc. ... JM Ocean Avenue. JM Ocean Avenue has secured ... Veretekk online automated marketing system. JM Ocean Avenue ... 2014 merger of Ocean Avenue and JM International, with ... $2 Billion per year company. , “After nearly 2 ...
(Date:12/15/2014)... Boston, MA (PRWEB) December 15, 2014 ... health management solutions, announced today that it has ... for Quality Assurance (NCQA) for its Disease Management ... obstructive pulmonary disease (COPD), coronary heart disease and ... accreditation from NCQA for Health Dialog’s Disease Management ...
(Date:12/15/2014)... 2014 Emergo Group, Inc., a medical ... in North and South America, Europe, the Middle East, ... participants for its 2015 Medical Device Industry Survey. Each ... upcoming business and market trends as well as regulatory ... targets areas including:, , Overall prospects ...
(Date:12/15/2014)... For the second year in a row, Bird Rock ... 2014.” Bird Rock Coffee Roasters’ Sumatra Ulos Batak came in ... 10. This is the first year that any roaster made ... on quality, value, and other aspects, including certifications and distinct ... and at $17.99 for 12-ounces, was also the most affordable ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... large proportion of Medicare expenditures for nursing home residents ... aggressive treatments that may be avoidable and of limited ... Institute for Aging Research, an affiliate of Harvard Medical ... Archives of Internal Medicine on Jan. 10, 2011. ...
... January 10, 2011 -- Previous research regarding the association ... later life suggests that mild to moderate alcohol consumption ... research has been conducted on subjects already rather elderly ... published in the December issue of the Journal ...
... MONDAY, Jan. 10 (HealthDay News) -- The H1N1 swine flu ... a vaccine that can protect people against multiple strains of ... were infected with the H1N1 virus and recovered had a ... variety of flu strains. The virus matched typical influenza ...
... MONDAY, Jan. 10 (HealthDay News) -- Patients given cholesterol-lowering drugs ... the brain may be at an increased risk of having ... well-known that statins help reduce the risk of heart disease ... in the brain. However, whether statins also benefit patients who ...
... quintessentially masculine, women in their fertile phase are more ... paired with George Clooney types. But women with ... their partners, a recent study co-authored by a University ... man,s intelligence has no effect on the extent to ...
... found that a protein that plays an important role in ... additional mechanisms that cause it to promote atherosclerosis, or clogging ... issue of the journal Arteriosclerosis, Thrombosis and Vascular Biology ... antioxidant therapies have not yielded more positive results. ...
Cached Medicine News:Health News:Aggressive care raises Medicare costs in end-stage dementia 2Health News:Aggressive care raises Medicare costs in end-stage dementia 3Health News:Abstinence, heavy drinking, binge drinking associated with increased risk of cognitive impairment 2Health News:People Who Recovered From H1N1 Offer Clues to Better Vaccine 2Health News:Statins May Be Harmful After Stroke 2Health News:Statins May Be Harmful After Stroke 3Health News:Men with macho faces attractive to fertile women, researchers find 2Health News:Men with macho faces attractive to fertile women, researchers find 3Health News:Protein thought to protect against oxidative stress also promotes clogging of arteries 2
(Date:12/13/2014)... 12, 2014 Mindray Medical International Limited ("Mindray", ... and marketer of medical devices worldwide, today announced shareholder ... held in Hong Kong on ... shareholders voted to re-elect incumbent directors Li Xiting and ... shareholders did not re-elect Peter Wan as ...
(Date:12/13/2014)... INDIANAPOLIS , Dec. 12, 2014  Novo Nordisk, a ... (CGRT), today announced a multi-year extension of their partnership, that ... No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by ... Kimball, 29, from Camarillo, California ... in the history of INDYCAR to win a race at ...
(Date:12/13/2014)... Dec. 11, 2014 Research and Markets ... of the "China Chemical Pharmaceutical Industry Report, ... http://photos.prnewswire.com/prnh/20130307/600769 ... preparation and active pharmaceutical ingredient (API), and the ... generally higher than that of the API over ...
Breaking Medicine Technology:Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 4Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 5Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 6Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 7China Chemical Pharmaceutical Industry Report, 2013-2016 2China Chemical Pharmaceutical Industry Report, 2013-2016 3
... 18 Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) ... is developing a potential cancer drug,that seeks to ... a pre-clinical product being developed by Aida,s Shanghai,Qiaer ... the,function of extracted fragments of Vasostatin, an inhibitor ...
... CARLSBAD, Calif., April 18 Isis,Pharmaceuticals, Inc. ... of two studies,designed to assess the impact ... Annual Atherosclerosis, Thrombosis and Vascular Biology (ATVB),Conference ... in a poster,entitled "Antisense Inhibition of Apolipoprotein ...
Cached Medicine Technology:Aida Announces New Anti-Cancer Drug Under Development 2Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis 2Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis 3Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis 4
Stainless Steel. Sterile. 2 pieces/box...
... attributes of the IMMULITE 2000, the IMMULITE ... Logic Driven Incubation (LDI). Using a newly ... be formatted for optimal performance with the ... assays, such as Siemens Diagnostics' cardiac biomarkers ...
... The SMS is a robotic sample feeder that ... systems via a robotic arm and the SMS ... 200 tubes and compatibility with clinical chemistry system ... make the SMS a practical and affordable solution ...
The properties of titanium alloy have been combined with a uniquely designed reverse radial tapping flute to produce a state-of-the-art fracture fixation system....
Medicine Products: